Calliditas Therapeutics AB Quarterly Research And Development Expense in SEK from Q2 2020 to Q2 2023

Taxonomy & unit
ifrs-full: SEK
Summary
Calliditas Therapeutics AB annual/quarterly Research And Development Expense history and growth rate from Q2 2020 to Q2 2023.
  • Calliditas Therapeutics AB Research And Development Expense for the quarter ending June 30, 2023 was 89M SEK, a 7.59% decline year-over-year.
  • Calliditas Therapeutics AB annual Research And Development Expense for 2023 was 502M SEK, a 21.1% increase from 2022.
  • Calliditas Therapeutics AB annual Research And Development Expense for 2022 was 415M SEK, a 16% increase from 2021.
  • Calliditas Therapeutics AB annual Research And Development Expense for 2021 was 357M SEK, a 48.1% increase from 2020.
Research And Development Expense, Quarterly (SEK)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 89M -7.3M -7.59% Apr 1, 2023 Jun 30, 2023 6-K 2023-08-17
Q2 2022 96.3M +21.3M +28.4% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-17
Q1 2022 113M +23.3M +25.8% Jan 1, 2022 Mar 31, 2022 6-K 2022-05-20
Q2 2021 75M +26.6M +55% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-19
Q1 2021 90.1M Jan 1, 2021 Mar 31, 2021 6-K 2022-05-20
Q2 2020 48.4M Apr 1, 2020 Jun 30, 2020 6-K 2021-08-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.